The Role and Mechanism of microRNA-1224 in Human Cancer

Mingwei Ma1,2†, Jie Li1,2†, Zimu Zhang1,2, Juan Sun1,2, Zhen Liu1,2, Ziyang Zeng1,2, Siwen Ouyang1,2 and Weiming Kang1,2*

1 Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2 Department of General Surgery, Peking Union Medical College Hospital, Beijing, China

microRNAs (miRNAs) are a type of small endogenous non-coding RNAs composed of 20-22 nucleotides, which can regulate the expression of a gene by targeting 3’ untranslated region (3’-UTR) of mRNA. Many studies have reported that miRNAs are involved in the occurrence and progression of human diseases, including malignant tumors. miR-1224 plays significant roles in different tumors, including tumor proliferation, metastasis, invasion, angiogenesis, biological metabolism, and drug resistance. Mostly, it serves as a tumor suppressor. With accumulating proofs of miR-1224, it can act as a potential bio-indicator in the diagnosis and prognosis of patients with cancer. In this article, we review the characteristics and research progress of miR-1224 and emphasize the regulation and function of miR-1224 in different cancer. Furthermore, we conclude the clinical implications of miR-1224. This review may provide new horizons for deeply understanding the role of miR-1224 as biomarkers and therapeutic targets in human cancer.

Keywords: miR-1224, cancer, tumor suppressor, function, clinical implication

INTRODUCTION

microRNAs (miRNAs) are endogenous non-coding small RNAs that are composed of 20-22 nucleotides and are widely present in eukaryotic cells (1). miRNAs regulate the cellular protein expression through binding to the 3’ untranslated region (3’-UTR) of the targeted mRNA, resulting in decreased or degraded expression of the target genes (2). Complete or incomplete binding of 6-8 nucleotide seed sequences of each miRNA can bind up to 100 mRNAs, leading to degradation or translation inhibition, respectively. Therefore, each miRNA can bind and regulate multiple mRNAs, and one mRNA can also be regulated by diverse miRNAs.

miRNAs are generated by endogenous transcribed primary transcripts, which are further cleaved by Drosha (RNase III) in the nucleus to produce stem-loop precursors miRNAs (pre-miRNAs) of approximately 70 nucleotides (3). Pre-miRNAs are transported by Exportin 5 from the nucleus to the cytoplasm and further processed by Dicer (RNase III) for the production of mature miRNAs (4, 5).

To date, more than 1600 miRNAs have been found and identified, most of which are highly conserved in mammalian species. The functions of miRNAs have been validated in developmental
timing, cell proliferation, cell differentiation, cell apoptosis, and tumorigenesis additionally (6–10). Considerable research revealed that miRNAs are dysregulated in different tumor types, which act as tumor inhibitors or tumor promoters and actively participate in the oncogenic process (11). In addition, miRNAs also play critical roles in predicting tumor classification, treatment response, and prognosis of patients (12).

miR-1224, located at chromosome 3q27.1, is a class of mammalian mirtron encompassed in the last intron of the VWA5B2 gene (von Willebrand factor A domain containing 5B2) and is discovered that acts vital roles in some diseases, such as acute liver failure, Parkinson’s disease, and cerebral ischemia (13–15). miR-1224 has two mature sequences, miR-1224-5p and miR-1224-3p, which perform different functions, respectively. Although some research has reported that miR-1224 expressed abnormally in several tumors, its biological function and specific mechanism in different cancers are still inconsistent (16–18). Moreover, the expression profile and its potential clinical significance of miR-1224 have not been investigated. Therefore, we systematically review the role and the detailed mechanism of miR-1224 in cancer, to gain a better comprehension of its potential role as biomarkers and therapeutic targets in cancer.

**MIR-1224 EXPRESSION IN HUMAN CANCER**

miR-1224 was expressed variously and mostly downregulated in human cancers (Table 1). The expression of miR-1224 in different kinds of tumors was showed followingly.

In the respiratory system, especially in lung cancer, miR-1224 was usually downregulated. miR-1224 was lower level detected by quantitative reverse transcription PCR (qRT-PCR) in lung cancer tissues than normal lung tissues (19). Zuo et al. found that miR-1224-3p was decreased in lung adenocarcinoma (LAUD) tissues compared to that in normal tissues via qRT-PCR method. Transcriptional profiling studies also showed that miR-1224-3p was remarkably reduced in LAUD cell lines (21). In the tissues of laryngeal papillomas (LP), further research proved that miR-1224-5p was greatly decreased by using qPCR. In addition, miR-1224-5p was downregulated in LP cell lines when compared to normal cells (20).

In the nervous system, miR-1224 was mostly downregulated in nervous system neoplasms (18, 23, 24). miR-1224-3p was reduced in glioma by using miRNA assay and real time PCR (23, 24), which was also observed in low-grade glioma (LGG)

| TABLE 1 | Expression profiles of miR-1224 in human cancers. |
|------------------|------------------|------------------|------------------|------------------|------------------|
| **Systems**       | **RNAs**         | **Cancer type**  | **Role**         | **Expression**   | **Sources**       | **References**   |
| Respiratory system | miR-1224         | LC               | tumor suppressor | downregulation   | tissue and cell   | (19)             |
|                   | miR-1224-5p      | LP               | tumor suppressor | downregulation   | tissue and cell   | (20)             |
|                   | miR-1224-3p      | LAUD             | tumor suppressor | downregulation   | tissue and cell   | (21)             |
| Nerve system      | miR-1224-3p      | LGG              | tumor suppressor | downregulation   | tissue           | (22)             |
|                   | miR-1224-3p      | Glioma           | tumor suppressor | downregulation   | tissue and cell   | (23)             |
|                   | miR-1224-5p      | Glioma           | tumor suppressor | downregulation   | tissue and cell   | (24)             |
| Muscular and skeletal systems | miR-1224-5p | GBM              | tumor suppressor | downregulation   | tissue and cell   | (25)             |
|                   | miR-1224-5p      | GBM              | tumor suppressor | downregulation   | GEO database      | (26)             |
| Nervous system    | miR-1224-5p      | OS               | tumor suppressor | downregulation   | tissue and cell   | (27)             |
|                   | miR-1224-3p      | OS               | tumor suppressor | downregulation   | tissue and cell   | (28)             |
| Genitourinary system | miR-1224-5p | BCa              | tumor suppressor | downregulation   | tissue and cell   | (29)             |
|                   | miR-1224-3p      | BCa              | tumor suppressor | downregulation   | tissue           | (30)             |
|                   | miR-1224-5p      | BCa              | tumor suppressor | upregulation     | tissue and cell   | (31)             |
| Digestive system  | miR-1224-3p      | BC               | tumor suppressor | upregulation     | cell             | (32)             |
|                   | miR-1224-5p      | TSCC             | tumor suppressor | downregulation   | cell             | (33)             |
|                   | miR-1224-5p      | OSCC             | tumor suppressor | downregulation   | tissue and cell   | (34)             |
|                   | miR-1224         | GC               | tumor suppressor | downregulation   | tissue and cell   | (35)             |
|                   | miR-1224-5p      | GC               | tumor suppressor | downregulation   | tissue and cell   | (36)             |
|                   | miR-1224         | intestinal-type GC | tumor suppressor | downregulation   | tissue and cell   | (37)             |
|                   | miR-1224-5p      | OROC             | tumor suppressor | downregulation   | tissue and cell   | (38)             |
|                   | miR-1224-5p      | OROC             | tumor suppressor | downregulation   | tissue and cell   | (39)             |
|                   | miR-1224-5p      | CRC              | tumor suppressor | downregulation   | tissue           | (40)             |
|                   | miR-1224-5p      | ESCC             | tumor suppressor | downregulation   | tissue and cell   | (41)             |
|                   | miR-1224-5p      | ESCA             | tumor suppressor | downregulation   | tissue and cell   | (42)             |
|                   | miR-1224         | HCC              | tumor suppressor | downregulation   | tissue and cell   | (43)             |
|                   | miR-1224-5p      | HCC              | tumor suppressor | downregulation   | cell             | (44)             |
|                   | miR-1224-5p      | PC               | tumor suppressor | downregulation   | tissue and cell   | (45)             |
|                   | miR-1224-5p      | PC               | tumor suppressor | downregulation   | tissue and cell   | (46)             |
| Skin              | miR-1224-5p      | Melanoma         | tumor suppressor | downregulation   | tissue and cell   | (47)             |
|                   | miR-1224-5p      | keloids          | tumor suppressor | downregulation   | tissue and cell   | (48)             |
from GEO and TCGA database (22). Qian et al. also confirmed that miR-1224-5p was downregulated in glioma by in situ hybridization of tissue samples (18). In glioblastoma (GBM), Xu et al. and Xiong et al. reported that miR-1224-5p acted as a tumor suppressor and a significant reduction of miR-1224-5p was detected in GBM tissues and cell lines via qRT-PCR and GEO database, respectively (25, 26).

Reduced miR-1224 was common in the muscular and skeletal system. For instance, miR-1224-5p was decreased in osteosarcoma (OS) tissues and cell lines by qRT-PCR (27, 28).

Similarly, miR-1224 was reduced in the digestive system. miR-1224-5p was downregulated in the cells of tongue squamous cell carcinoma (TSCC) and oral squamous cell carcinoma (OSCC) by RT-qPCR analysis (33, 34). In gastric cancer (GC), miR-1224 was reduced in GC tissues and cell lines through RT-PCR analysis (35–37). In colorectal cancer (CRC), miR-1224-5p also acted as a tumor suppressor and a significant reduction of miR-1224-5p was detected in CRC tissues and cell lines according to qRT-PCR, western blot, and immunohistochemistry (17, 38, 39). In hepatocellular carcinoma (HCC) and pancreatic cancer (PC), miR-1224 showed a descending trend, especially the miR-1224-5p according to bioinformatics analysis (GEO datasets), RNA sequencing and qRT-PCR validation (42–46). Not only that, but miR-1224-5p also declined in esophageal squamous cell carcinoma (ESCC) and esophageal cancer (ESCA) tissues compared to normal tissues by qRT-PCR (40, 41).

miR-1224 was somewhat controversial in the genitourinary system. Through qRT-PCR experiments, miR-1224 was found downregulated in bladder cancer (BCa) (29, 30). However, Ding et al. reported that miR-1224-5p was elevated in the BCa tissues and cell lines using TCGA database (31). Similarly, Ran et al. found that miR-1224-3p was increased in breast cancer (BC) cells by using RT-qPCR methods (32).

In skin system, miR-1224-5p was significantly downregulated in melanoma tissues and cell lines by using qRT-PCR (47). miR-1224-5p was also downregulated in keloids from miRNA microarray and qRT-PCR (48).

Those data proved that there was wide diversity for miR-1224 expression in different cancers, sometimes even in same cancer.

THE REGULATION OF MIR-1224 IN HUMAN CANCER

Generated by non-coding mRNA splicing, miR-1224 was regulated by multiple signaling molecules such as CREB1, SND1, and β-catenin (Table 2). LncRNAs mainly performed as ceRNA to sponge miRNAs and thus to regulate miRNA expression. In LC, miR-1224 was repressed by long-chain non-coding RNA (lncRNA) NEAT1, thereby upregulating KLF3 expression (19). LncRNA NEAT1 also regulated miR-1224-5p in GC by sponging miR-1224-5p, thus regulating RSF1 expression and in turn, altering the evolution of GC (36). Additionally, Linc00460 regulated miR-1224-5p in OS and ESCA, respectively (28, 41). Linc00460 functioned as a molecular sponge to absorb miR-1224-5p, thereby promoting metastasis and epithelial-to-mesenchymal transition (EMT) of ESCA and OS progression (28, 41). There were other lncRNAs to regulate miR-1224 besides LncRNA NEAT1 and Linc00460. Linc00665 was the sponge for miR-1224-5p, which elevated the SND1 in PC cells (46). Zhao et al. discovered that LncRNA IGLFL2-AS1 played an oncogenic role in TSCC (33). It interacted with miR-1224-5p to regulate SATB1, which activated the transcriptional activity of Wnt/β-catenin in TSCC cells (33). LncRNA ZEB1-AS1 was generated from the promoters of ZEB1, which played a vital role in tumorogenesis. Experimental data indicated that ZEB1-AS1 directly regulated miR-1224-5p, thus controlling the processes of development and progression in melanoma (47). To sum up, several articles have confirmed that multiple lncRNA molecules are involved in the regulation of miRNA, mainly acting as sponges to inhibit miRNA expression.

Circular RNAs (circRNAs) are identified as a type of endogenous non-coding RNAs and exist conserved miRNA target sites, and therefore circRNAs could act as miRNA sponges to modulate its expression. Circ-CASC15 was highly expressed in BCa, which directly bind to miR-1224-5p. Consequently, CREB1, the target of miR-1224-5p, was increased in BCa (29). Recent studies have shown that circ-EGLN3 was involved in RCC tumorigenesis through downregulating miR-1224-3p, which targeted HMGXB3, thus regulating proliferation, invasion, and migration (49). CircRNAs also played an important role in the progression of digestive system neoplasms, such as circ-RASGRF2 and circ-RNF121 (38, 43). Circ-RASGRF2 was originated from RASGRF2 and identified to be remarkably upregulated in HCC. Further data confirmed that circRASGRF2 facilitated the expression of FAK by sponging miR-1224. The knockdown of circ-RASGRF2 inhibited the proliferation and migration of HCC cells. (43). Circ-RNF121 was remarkably upregulated in CRC. Similarly, circ-RNF121 functioned as a sponge of miR-1224-5p to regulate cell growth, migration, and invasion in CRC (38). Zuo et al. found that circ-ZNF609 sponged miR-1224-3p to downregulate its expression in LAUD. As a result, the molecular target of miR-1224-3p, ETV1, was upregulated in LAUD. Recently, ETV1 has been identified to play an oncogenic role (21). In nerve system, Circ-ZNF609 functioned as a miR-1224-3p sponge and mediated cell behaviors in glioma. It promoted cell proliferation and metastasis by promoting PLK1 via binding to miR-1224-3p competitively (24). Other regulatory factors modulated miR-1224-3p expression in gliomas, such as EZH2 and MIR4435-2HG (lncRNA MIR4435-2 Host Gene) (23, 25). EZH2, a core component of PRC2, acted as a histone methyltransferase that trimethylated histone 3 at lysine 27 (H3K27me3), silencing the gene. In gliomas, miR-1224-3p was inhibited by EZH2, which in turn regulated β-catenin expression through binding to its 3′ UTR, thus controlling proliferation, invasion, and glucose metabolism of cells (23). MIR4435-2HG belonged to long non-coding RNAs and was involved in the regulation of brain tumor progression. Knockdown of MIR4435-2HG contributed to the inhibition of cell proliferation and invasion of GBM. MIR4435-2HG suppressed miR-1224-5p expression through similar mechanism (25).
THE FUNCTION OF MIR-1224 IN HUMAN CANCER

As a tumor suppressor, miR-1224 significantly inhibited the proliferation, migration, and invasion and induced apoptosis of cancer cells (33). Additionally, miR-1224 participated in the process of the cell cycle, apoptosis, autophagy, and EMT to repress development of tumor (40). Also, miR-1224 influenced metabolic behavior such as glucose metabolism to inhibit the cell growth of cancer (1). Interestingly, miR-1224 promoted the migratory ability of cells and induced EMT in BCa and triple-negative breast cancer (TNBC) (32, 50). In the following part, we systematically proposed the functions of miR-1224, including oncogenic factors and tumor suppressors (Figure 1).

INHIBITION OF THE CANCEROGENIC PROCESS

Proto-oncogenes normally promoted cell division and proliferation, playing a vital role in the early stages of growth and development. When proto-oncogenes mutated, such as...
point mutation, gene amplification, chromosomal translocation, promoter insertion, the proto-oncogenes were over-activated and transformed to oncogenes, resulting in excessive cell growth, eventually leading to the initiation and progression of tumors. Abundant studies have found that FOXM1, as an oncogene, was generally highly expressed in tumors. Furthermore, it was implicated in all key features of the cancers described by Hanahan and Weinberg. FOXM1 induced oncogenic WNT and TGFβ signaling pathways by interacting with other proteins such as β-catenin or SMAD3 (51). Jiang et al. revealed that miR-1224 can bind to FOXM1 in CRC cells and inhibited its function, thus blocking the occurrence of cancer (38). Similarly, the oncogenic effects of other oncogenes, such as SP1, RSF1, and SND1, were attenuated when miR-1224 was co-present with them (36, 39, 52).

**PROMOTION OF CELL APOPTOSIS AND AUTOPHAGY**

Currently, many anti-cancer therapies were targeting molecules involved in cell apoptosis regulation (53–55). BCL2 and BAD belonged to the BCL2 family, which controlled the internal apoptosis pathway. On the whole, BCL2 played a part in anti-apoptotic, while BAD played a part in pro-apoptotic. Recent studies have indicated that NSD2 deficiency repressed the expression of BCL2 but upregulated the expression of BAD (55). However, NSD2 appeared to play an anti-apoptotic role in OSCC cells, and its elevated expression was associated with the poor prognosis of OSCC patients. However, miR-1224 reversed the anti-apoptotic effects of NSD2 and promoted cell apoptosis by binding to NSD2 (34). SATB1 and FAK played an active function in the apoptotic cleavage of cellular proteins, similarly, miR-1224 accelerated the cell apoptosis via targeting SATB1 and FAK in cancer (33, 43). Autophagy was a conserved catabolic biological process widely existing in eukaryotes and lysosomes that participated in digestion and degradation of their macro molecules or damaged organelles to finish their biological functions (56). Autophagy was a double-edged sword in tumor progression (57). It can not only inhibit the formation of tumors but also assist cells to fight against hypoxic condition, lack of nutritional factors, and other adverse growth environments, thus boosting the initiation and progression of tumors. Zhao et al. discovered that FADS1 regulated the process of autophagy in laryngeal squamous cell carcinoma through activating AKT/mTOR signaling (58). A recent study found that miR-1224 restrained the expression of FADS1 in OS (28). Therefore, miR-1224 played a role in promoting autophagy through binding to different targets. Not only that, but miR-1224-5p also inhibited OS autophagy by targeting the PLK1-mediated PI3K/AKT/mTOR pathway. It was well known that autophagy-related molecules such as LC3-II/I, P62, and Beclin-1 can regulate autophagy activity during the autophagy process. Jin et al. have found that miR-1224-5p significantly facilitated the
expression of LC3II/I and Beclin-1 which were autophagy-related in OS by targeting PLK1 (27).

SUPPRESSION OF CELL INVASION

The invasion of a malignant tumor referred to the invasion and diffusion of cells to the surrounding environment. The direct diffusion of cells to the surrounding area without separating from the main body of the tumor was called direct diffusion without metastasis. Cells invaded blood vessels, lymphatics, and body cavities, then were removed from the main body of the tumor and continued to grow in distant organs, forming new tumors of the same type, which was called metastasis. The highly invasive characteristics of tumors were associated with a poor prognosis. Uregulated MMPs were involved in cell migration and invasion (59). Oh et al. disclosed that MMPs were regulated by ETVs, and emphasized that ETV1 was the most important one (60). Recent studies demonstrated that miR-1224 bind to the 3’-UTR of ETV1 to reduce its expression, and overexpressed miR-1224 suppressed ETV1 and MMPs, which significantly inhibited the invasion of cells (21). miR-1224 blocked the translation of KLF3 by binding to the mRNA, and inhibition of miR-1224 led to an increase of KLF3, thus enhancing the aggressiveness of cells (19). These results suggested that miR-1224 played a critical role in the regulation of cell migration and invasion through directly interacting with ETV1 and regulating MMPs, known targets of ETV1.

INDUCTION OF CELL CYCLE ARREST

Mitosis is one of the most important steps in the cell cycle (57). Du et al. reported that miR-1224 was frequently downregulated in glioma, the miR-1224-3p inhibitor significantly reduced the expression of miR-1224-3p and remarkably accelerated the cell proliferation. Another study discovered that miR-1224-3p was bound to PLK1, which was involved in mitosis and the cell cycle. The abovementioned data revealed that miR-1224-3p inhibited tumor growth by directly binding to PLK1 (24). OGFPD1, a stress granule protein, was linked closely to cell cycle G1/2 and G1/M. Recent studies found a significantly increased expression of OGFPD1 in LP tissues and cells, which was associated with the promotion of cell viability and proliferation in LP. Overexpressed miR-1224-5p significantly inhibited OGFPD1-induced cell proliferation and activity by targeted OGFPD1 (20).

ROLE IN EMT

Multiple studies showed that reduced miR-1224 enhanced the invasion and metastasis of a variety of tumors. Oh et al. discovered that miR-1224 was downregulated in the process of EMT (60). In addition, miR-1224 indirectly affected differentiation and EMT by inhibiting metastasis through a network of pre-metastasis stimulators that targeted VEGF, COX2, and MMP9, which were involved in angiogenesis, collagen remodeling, and proteolysis (21).

TUMOR-ONCOGENIC ROLE IN SOME TUMORS

miR-1224 not only acted as a tumor suppressor but sometimes as an oncogene that promoted tumor genesis and development (Figure 2). As we all known, one of the signature features of cancer cells was metabolic reprogramming of aerobic glycolysis. PGM5 (A member of the phosphoglucomutase (PGM) group superfamily) catalyzed the bidirectional interconversion metabolism of glucose-1-phosphate (G1P) and glucose-6-phosphate (G6P). A recent study found that miR-1224-3p promoted cell proliferation and migration via PGM5-mediated aerobic glycolysis in BC (32). Another study revealed that the high expression of miR-1224-3p was an independent prognostic indicator of poor overall survival of TNBC patients. miR-1224-3p bound to TUSC7, which inhibited cell growth, proliferation, and metastasis both in vitro and in vivo in BC (50).

CLINICAL IMPLICATION

The occurrence of the tumor was caused by many factors, and its progression was directly related to the therapeutic effects of patients (61). Therefore, early diagnosis and individual treatment were critical for the patients to prolong their survival. Tumor markers were widely used in the screening of many tumors, but the low sensitivity of tumor markers made the results inaccurate and conflicting (62). The differential expression of miRNAs in tumor tissues became the focus of research, which can be combined with the detection of tumor markers to facilitate the screening and prognosis of tumors.

Many research indicated that miR-1224 can be used as a prognostic biomarker in clinical practice (Table 3). When miR-1224 acted as tumor-suppressors, reduced miR-1224 indicated a short overall survival for patients with malignant tumors. Zhao et al. compared the expression of miR-1224-5p in TSCC cells with that in normal cells and found that miR-1224-5p was decreased in TSCC cells, suggesting miR-1224 may aid as a new biomarker contributing to TSCC treatments (33). Patients who developed with III+IV stage had a higher miR-1224 expression, suggesting that it can act as a brand-new biomarker for GC patients (35). Wang et al. reported that miR-1224-5p was negatively correlated with lymph node metastasis and FIGO stage in OC, indicating miR-1224-5p was associated with survival of patients with OC (52). Shi et al. found that decreased miR-1224-5p was associated with a high TNM stage thus are an unfavorable prognostic factor for ESCC patients (40). Patients with decreased miR-1224-5p had a poor survival probability (P=0.006) in PC (45). Most Studies demonstrated that miR-1224 served as a blood-based biological indicator for early diagnosis and potential prognostic biomarker in BCa, melanoma, keloid (29, 47, 48). In contrast, Zheng et al. found...
that high miR-1224-3p expression was an independent clinical blood-based factor of poor OS for TNBS patients (50).

Additionally, miR-1224 can act as therapeutic targets in cancer treatment through understanding its mechanism and function (Table 3). Zhang et al. demonstrated that the miR-1224-3p/HMGXB3 axis can be used as a target for the treatment of RCC (49). Yang et al. identified a miR-1224/CREB feedback loop, suggesting that blocking this circuit can be a potential molecular treatment for HCC patients (42). Similarly, miR-1224-3p/PGM5 axis played a vital role in cell proliferation, metastasis, and migration, and may be a potential target for therapy of BC (32). Li et al. demonstrated that miR-1224-5p/NSD2 axis participated in the resistance to chemotherapy of 5-FU in OSCC, providing a novel target (34). MiR-1224 can be used as a therapeutic target for CRC, GC, and LAUD in given that abundant research (17, 21, 35, 39).

CONCLUSIONS AND PROSPECTS

At present, diverse tumors with high morbidity and mortality brought heavy burdens for patients and their families. Many studies contributed to revealing the etiology of tumor occurrence and exploring effective therapeutic methods. However, the mechanism of tumor genesis, metastasis, and drug resistance is still not clear. Researchers found that miR-1224 expression in many tumor tissues and cells was significantly different from those in normal tissues and cells. miR-1224 mostly acted as a tumor suppressor in tumor initiation and development, including proliferation, metastasis, blood formation, invasion, and drug resistance. Studies have shown that miR-1224 can be used as a tumor biomarker for early diagnosis and prognosis prediction in the future.

In conclusion, with further research on miR-1224, the mechanism of miR-1224 in the occurrence and development of
tumors will be gradually revealed. miR-1224 can not only serve as an indicator of tumor diagnosis and prognosis but also become an effective target for tumor therapy, providing a new direction for targeted precision therapy.

**AUTHOR CONTRIBUTIONS**

MM, JL, and WK generated this conception. MM and JL wrote this manuscript and were co-first authors. JS and ZMZ searched and collected the relative articles. ZL, ZYZ, and SO collected the data and produced the tables and figures. WK supervised and revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was funded by the CSCO-ROCHE Research Fund (No. Y-2019 Roche-015), Beijing Xisike Clinical Oncology Research Foundation (Y-HS2019-43), Wu Jieping Medical Foundation, (No. 320, 6750.19020, No. 320.6750.2020-08-32), and CAMS Innovation Fund for Medical Sciences (2020-I2M-C&T-B-027).

**REFERENCES**

1. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of Novel Genes Coding for Small Expressed RNAs. *Science* (2001) 294:853–8. doi: 10.1126/science.1064921
2. Bhaskaran M, Mohan M. MicroRNAs: History, Biogenesis, and Their Evolving Role in Animal Development and Disease. *Vet Pathol* (2014) 51:759–74. doi: 10.1177/0300985813502820
3. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The Nuclear RNase III Drosha Initiates microRNA Processing. *Nature* (2003) 425:415–9. doi: 10.1038/nature01957
4. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 Mediates the Nuclear Export of Pre-microRNAs and Short Hairpin RNAs. *Genes Dev* (2003) 17:3011–6. doi: 10.1101/gad.1158803
5. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, et al. TRBP Recruits the Dicer Complex to Ago2 for microRNA Processing and Gene Silencing. *Nature* (2005) 436:740–4. doi: 10.1038/nature03868
6. Tsuchiya S, Okuno Y, Tsujimoto G. MicroRNA: Biogenetic and Functional Mechanisms and Involvements in Cell Differentiation and Cancer. *J Pharmocol Sci* (2005) 101:267–70. doi: 10.1254/jps.106013X
7. Cho WC, OncomiRs: The Discovery and Progress of microRNAs in Cancers. *Mol Cancer* (2007) 6:60. doi: 10.1186/1476-4598-6-60
8. Liu J. Control of Protein Synthesis and mRNA Degradation by microRNAs. *Curr Opin Cell Biol* (2008) 20:214–21. doi: 10.1016/j.ceb.2008.01.006
9. Drakaki A, Iliopoulos D. MicroRNA Gene Networks in Oncogenesis. *Curr Genomics* (2009) 10:35–41. doi: 10.2174/138920209787581299
10. Tzur G, Israel A, Levy A, Benjamini H, Meiri E, Shufaro Y, et al. Comprehensive Gene and microRNA Expression Profiling Reveals a Role for microRNAs in Human Liver Development. *PloS One* (2009) 4,e7511. doi: 10.1371/journal.pone.0007511
11. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. *Curr Genomics* (2010) 11:537–61. doi: 10.2174/138920210793175895
12. Calin GA, Croce CM. MicroRNA Signatures in Human Cancers. *Nat Rev Cancer* (2006) 6:857–66. doi: 10.1038/nrc1997
13. Hunsberger JG, Fessler EB, Wang Z, Elkahloun AG, Chuang DM. Post-Insult Valproic Acid-Regulated microRNAs: Potential Targets for Cerebral Ischemia. *Am J Transl Res* (2012) 4 (3): 316–32. www.ajtr.org /ISSN:1943-8141/AJTR1207001
14. Sibley CR, Seow Y, Curtis H, Weinberg MS, Wood MJ. Silencing of Parkinson’s Disease-Associated Genes With Artificial Mirtron Mimics of miR-1224. *Nucleic Acids Res* (2012) 40:9863–75. doi: 10.1093/nar/gks712
15. Roy S, Bantel H, Wadrer F, Schneider AT, Gautheron J, Vucur M, et al. miR-1224 Inhibits Cell Proliferation in Acute Liver Failure by Targeting the Antia apoptotic Gene Nfj. *J Hepatol* (2017) 67:966–78. doi: 10.1016/j.jhep.2017.06.007
16. Nymark P, Guedel M, Borze I, Faisal A, Lahti L, Salmenkivi K, et al. Integrative Analysis of microRNA, mRNA, and scDNA Data Reveals Asbestos- and Histology-Related Changes in Lung Cancer. *Genes Chromosomes Cancer* (2020) 59:585–97. doi: 10.1002/gcc.20880

17. Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundstrom J, Ristamaki R, et al. microRNA Profiling Predicts Survival in Anti-EGFR Treated Chemoradiotherapy Metastatic Colorectal Cancer Patients With Wild-Type KRAS and BRAF. *Cancer Genet* (2012) 205:545–51. doi: 10.1016/j.crcgen.2012.08.003

18. Qian J, Li R, Wang YY, Shi Y, Luan WK, Tao T, et al. MiR-1224-5p Acts as a Tumor Suppressor by Targeting CREB1 in Malignant Gliomas. *Mol Cell Biochem* (2015) 403:33–41. doi: 10.1007/s10010-015-2334-1

19. Yu PF, Wang Y, Lv W, Kou D, Hu HL, Guo SS, et al. LncRNA NEAT1/miR-1224/KLF3 Contributes to Cell Proliferation, Apoptosis and Invasion in Lung Cancer. *Eur Rev Med Pharmacol Sci* (2019) 23:8403–10. doi: 10.26355/eurrev_2019010_19151

20. Yin D, Wang Q, Wang S, Zhu G, Tang Q, Liu J. OGFOD1 Negatively Regulated by miR-1224-5p Promotes Proliferation in Human Papillomavirus-Infected Laryngeal Papillomas. *Mol Genet Genomics* (2020) 295:675–84. doi: 10.1007/s00438-020-01649-x

21. Zuo Y, Shen W, Wang C, Niu N, Pu J. Circular RNA Circ-ZNF609 Promotes Lung Adenocarcinoma Proliferation by Modulating miR-1224-3p/ETV1 Signaling. *Cancer Manag Res* (2020) 12:2471–9. doi: 10.2147/CMM.232260

22. Wang Y, Cui Y, Jin B, Yang Y, Peng Y. Comprehensive Bioinformatics Analysis of mRNA Expression Profiles and Identification of a mRNA-miRNA Network Associated With the Pathogenesis of Low-Grade Gliomas. *Cancer Manag Res* (2021) 15:5315–47. doi: 10.2147/CMM.S140111

23. Wang Y, Wang M, Wei W, Han D, Chen X, Hu Q, et al. Disruption of the EZH2/miRNA-B-Catenin Signaling Suppresses Aerobic Glycolysis in Glioma. *Oncotarget* (2016) 7:49450–8. doi: 10.18632/oncotarget.10370

24. Du S, Li H, Lu F, Zhang S, Tang J. Circular RNA ZNF609 Promotes the Malignant Progression of Glioma by Regulating miR-1224-3p/PLK1 Signaling. *J Cancer* (2021) 12:3534–46. doi: 10.7150/jca.54934

25. Xu H, Zhang B, Yang Y, Li Z, Zhao P, Wu W, et al. LncRNA MIR4435-2HG Potentiates the Proliferation and Invasion of Giblastoma Cells via Modulating miR-1224-5p/TGFBR2 Axis. *J Cell Mol Med* (2020) 24:5632–72. doi: 10.1111/jcmm.15280

26. Xiong DD, Xu WQ, He RQ, Dang YW, Chen G, Luo DZ. In Silico Analysis of microRNA, mRNA and aCGH Data Reveals Asbestos- and Histology-Related Changes in Lung Cancer. *Cancer Manag Res* (2021) 13:11807. doi: 10.2147_CMAR.S314011

27. Jin B, Jin D, Zhao Z, Zhang B, Chen K. MiR-1224-5p Activates Autophagy, Cell Invasion and Inhibits Epithelial-To-Mesenchymal Transition in Osteosarcoma Cells by Directly Targeting PLK1 Via PI3K/AKT/mTOR Signaling Pathway. *Onco Targets Ther* (2020) 13:11807–18. doi: 10.2147/OTT.S248507

28. Lian H, Xie P, Yin N, Zhang J, Zhang X, Li J, et al. Linc00460 Promotes Osteosarcoma Proliferation via miR-1224-5p/FADS1 Axis. *Life Sci* (2021) 233:116757. doi: 10.1016/j.lfs.2021.116757

29. Huang C, Huang X, Yu J, Gui Y. Circular RNA Hsa_Circ_0075828 Promotes Bladder Cancer Cell Proliferation Through Activation of CREB1. *BMB Rep* (2020) 53:82–7. doi: 10.4584/BMBRep.2020.53.2.059

30. Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, et al. APCDD1L-AS1 Induces 5-Fluorouracil Resistance in Oral Squamous Cell Carcinoma Progression Through Activation of CREB1. *Oncotarget* (2016) 7:10229–39. doi: 10.18632/oncotarget.10333

31. Sun F, Shi Z, Fu S, Li Q, Li B, Sang L, et al. Exosomal-Mediated Transfer of APCDD1L-AS1 Induces 5-Fluorouracil Resistance in Oral Squamous Cell Carcinoma via miR-1224-5p/Nuclear Receptor Binding SET Domain Protein 2 (NSD2) Axis. *Bioengineered* (2021) 12:7188–204. doi: 10.1080/21655979.2021.1979442

32. Ran F, Zhang Y, Shi Y, Liu J, Ding L, et al. miR-1224-3p Promotes Breast Cancer Cell Proliferation and Migration Through PGM5-Mediated Aerobic Glycolysis. *J Oncol* (2021) 2021:5529770. doi: 10.1155/2021/5529770

33. Zhao R, Wang S, Tan L, Li H, Jia Z, Zhang S. IGFL2-AS1 Facilitates Tongue Squamous Cell Carcinoma Progression via Wnt/beta-Catenin Signaling Pathway. *oral Dis* (2021). doi: 10.1111/odi.13935

34. Li S, Shi Z, Fu S, Li Q, Li B, Sang L, et al. Exosomal-Mediated Transfer of miR-1224 in Salivary Gland Tissue and Its Significance in Oral Cancer. *Cancer Manag Res* (2021). doi: 10.2147/CMM.S305865

35. Gartel AL. FOXM1 in Cancer: Interactions and Vulnerabilities. *Biochem Biophys Res Commun* (2015) 403:33

36. Wang Q, Zhang R, Liu D. Long Non-Coding RNA ZEB1-AS1 Indicates Poor Prognosis and Promotes Melanoma Progression Through Targeting miR-1224-5p. *Exp Ther Med* (2019) 17:857–62. doi: 10.3892/etm.2018.7005

37. Cui X, Xiu W, Xu X, Hu P, Zhu W, Chen X, et al. Tumor Suppressive Role of miR-1224-5p in Keoid Proliferation, Apoptosis and Invasion via the TGF-Beta1/Smad3 Signaling Pathway. *Biochem Biophys Res Commun* (2018) 495:713–20. doi: 10.1016/j.bbrc.2017.10.070

38. Zhang BH, He ZX, Zhang J, Ma JJ, Zhang HW, Zhu W, et al. The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer. *Cancer Manag Res* (2021) 13:5763–74. doi: 10.2147/CMAR.S305865

39. Sun ZP, Zhang J, Shi LH, Zhang XR, Duan Y, Xu WF, et al. Aminopeptidase N Inhibitor 4cS Synergizes Antitumor Effects of 5-Fluorouracil on Human Liver Cancer Cells Through ROS-Dependent CD13 Inhibition. *BioMed Pharmacother* (2015) 76:65–72. doi: 10.1016/j.biopha.2015.10.023

40. Velez C, Soto J, Rios K, Silva L, Hernandez W, Rivera LA, et al. Toxicity and Apoptosis Related Effects of Benzenimidazol [3,2-alpha]-Quinolinium Salts
Upon Human Lymphoma Cells. *Open Med Chem J* (2017) 11:54–65. doi: 10.2174/18741045017111010054

55. He C, Liu C, Wang L, Sun Y, Jiang Y, Hao Y. Histone Methyltransferase NSD2 Regulates Apoptosis and Chemosensitivity in Osteosarcoma. *Cell Death Dis* (2019) 10:65. doi: 10.1038/s41419-019-1347-1

56. Kim KH, Lee MS. Autophagy—a Key Player in Cellular and Body Metabolism. *Nat Rev Endocrinol* (2014) 10:322–37. doi: 10.1038/nrendo.2014.35

57. Henriques AC, Ribeiro D, Pedrosa J, Sarmento B, Silva PMA, Bousbaa H. Mitosis Inhibitors in Anticancer Therapy: When Blocking the Exit Becomes a Solution. *Cancer Lett* (2019) 440-441:64–81. doi: 10.1016/j.canlet.2018.10.005

58. Zhao R, Tian L, Zhao B, Sun Y, Cao J, Chen K, et al. FADS1 Promotes the Progression of Laryngeal Squamous Cell Carcinoma Through Activating AKT/mTOR Signaling. *Cell Death Dis* (2020) 11:272. doi: 10.1038/s41419-020-2457-5

59. Brinckerhoff CE, Matrisian LM. Matrix Metalloproteinases: A Tail of a Frog That Became a Prince. *Nat Rev Mol Cell Biol* (2002) 3:207–14. doi: 10.1038/nrm763

60. Oh S, Shin S, Janknecht R. ETV1, 4 and 5: An Oncogenic Subfamily of ETS Transcription Factors. *Biochim Biophys Acta* (2012) 1826:1–12. doi: 10.1016/j.bbacli.2012.02.002

61. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer Statistics for the Year 2020: An Overview. *Int J Cancer* (2021) 149. 778–89. doi: 10.1002/ijc.35388

62. Sauerbrei W, Taube SE, Mchane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. *J Natl Cancer Inst* (2018) 110:803–11. doi: 10.1093/jnci/djy088

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ma, Li, Zhang, Sun, Liu, Zeng, Ouyang and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.